Recent Trends in Preparation of Poly(lactide-co-glycolide) Nanoparticles by Mixing Polymeric Organic Solution with Antisolvent

Table 2

Summary of processing conditions of w₁/o/w₂ emulsion methods and major characteristics of PLGA nanoparticles.

Polymer (grade)	Solvent	Polymer %	Drug	D/P	Size (nm)	EE (%)	Reference
Galactose-PLGA (n/a)	DCM-acetone	n/a	Acyclovir	10	198	61	[46]
mPEG-PLGA-b-PLL (42.3 kDa)	Chloroform	1	Adriamycin	8	170	86	[47]
RG502H (n/a)	DCM	n/a	Bevacizumab	n/a	197	82	[48]
PLGA50 : 50 (91.6–120 kDa)	Chloroform	5	BSA	n/a	290	65	[49]
RG503 (34 kDa)	DCM	5	BSA	1	246	84	[50]
PLA-TPGS (25.3 kDa)	DCM	1.5	BSA	6.7∼40	325∼329	53∼80	[51]
PLGA50 : 50 (0.4 dL/g)	DCM	5	BSA	10	300	53	[52]
PLGA50 : 50 (30–60 kDa)	DCM	1	CTP (52 kDa)	n/a	272	60	[53]
PLGA (n/a)	DCM-acetone	1.25	CAA	0.8	187	76	[54]
PLGA50 : 50 (1,234 kDa)	Chloroform	3	pDNA (7.3 kbp)	0.55∼1.1	538∼644	9∼32	[55]
PLGA50 : 50 (40–75 kDa)	DCM	0.1∼5	Doxorubicin	2∼100	100	35∼85	[56]
PLGA50 : 50-chitosan (n/a)	DCM	n/a	Exendin-4	n/a	275∼310	n/a	[57]
PLGA50 : 50-chitosan (15 kDa)	DCM	1.67	5-Fluorouracil	10	198∼280	23∼29	[58]
R502H (12 kDa)	DCM	5	Gentamicin	3.5	241∼252	6∼22	[59]
RG502H (13.8 kDa)	EA	n/a	Gentamicin	1∼5	320	13∼47	[60]
PLGA75 : 25 (20 kDa)	DCM	3, 6, 20	GFP siRNA	0.24, 0.6	224∼428	11∼58	[61]
RG503 (34 kDa)	DCM	5	Insulin	5	276	68	[50]
RG503H (n/a)	DCM	1.5	hgp100, TRP2	1	80	8∼40	[62]
PLGA50 : 50 (30 kDa)	DCM	3.3	LA	0.2, 3.85	300	49∼72	[63]
RG502H (10–12 kDa)	DCM	3	Ovalbumin	1.67	182	54	[64]
PLGA50 : 50 (7–17 kDa)	DCM	2.9	Ovalbumin	20	358	36	[65]
PLGA50 : 50 (40–75 kDa)	DCM	2	PEI-rhodamine B	0.5	117∼130	45∼75	[66]
PLGA50 : 50 (n/a)	DCM	n/a	pRedN-1 DNA	n/a	998	10	[67]
PLGA50 : 5 (45–75 kDa)	DCM	1∼5	TIMP-1 (28 kDa)	0.2∼1.0	81∼433	62∼80	[68]

Note: n/a, not available, not specified.
All abbreviations are the same as those described in Table 1; BSA, bovine serum albumin; CTP, Chlamydia trachomatis protein; CAA, collagen adhesin antigen; LA, Leishmania antigen; TIMP-1, tissue inhibitor of matrix metalloproteinase-1.